GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Cash Paid for Insurance Activities

NLSP (NLS Pharmaceutics) Cash Paid for Insurance Activities


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Cash Paid for Insurance Activities?

Cash Paid for Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.


NLS Pharmaceutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.